A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)

NCT01984697 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1518

Enrollment

INDUSTRY

Sponsor class

Conditions

Human Papillomavirus Infection

Interventions

BIOLOGICAL: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)

Sponsor

Merck Sharp & Dohme LLC